Ethylisopropyltryptamine

Chemical compound
  • none
Legal statusLegal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
  • N-ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-2-amine
CAS Number
  • 848130-11-0 checkY
ChemSpider
  • 21106305 checkY
UNII
  • 63J8CXV5Z8
Chemical and physical dataFormulaC15H22N2Molar mass230.355 g·mol−13D model (JSmol)
  • Interactive image
Melting point71 to 73 °C (160 to 163 °F)
  • CCN(C(C)C)CCc1c[nH]c2ccccc12
InChI
  • InChI=1S/C15H22N2/c1-4-17(12(2)3)10-9-13-11-16-15-8-6-5-7-14(13)15/h5-8,11-12,16H,4,9-10H2,1-3H3 checkY
  • Key:HQZLBYMOYCJZRF-UHFFFAOYSA-N checkY
  (verify)

Ethylisopropyltryptamine (EiPT) is a chemical of the tryptamine family that and produces psychedelic and hallucinogenic effects. It was probably first synthesized by American psychopharmacologist, Alexander Shulgin.

Chemistry

EiPT is short for N-ethyl-N-isopropyl-tryptamine. The full chemical name of this structure is N-ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-2-amine. EiPT is a tryptamine, which all belong to a larger family of compounds known as indolethylamines. EiPT is closely related to the compounds diethyltryptamine (DET) and DIPT.

Dosage

In his book TiHKAL, Alexander Shulgin lists a dosage for EiPT as being 24-40 mg taken orally.

Effects

Very little is known about the psychopharmacological properties of EiPT, but reports suggest it produces psychedelic effects that can last 4–6 hours. According to Shulgin, this compound tends to produce nausea, dysphoria, and other unpleasant side-effects. It also lacks the hallucinatory and visual properties usually associated with psychedelic drugs.

Dangers

There have been no reported deaths or hospitalizations from EiPT, but its safety profile is unknown.

Legality

EiPT is unscheduled and uncontrolled in the United States, but possession and sales of EiPT could be prosecuted under the Federal Analog Act because of its structural similarities to DET.

See also

External links

  • EiPT entry from TiHKAL
  • EiPT entry in TiHKAL • info
  • v
  • t
  • e
Psychedelics
(5-HT2A
agonists)
Benzofurans
Lyserg‐
amides
Phenethyl‐
amines
2C-x
25x-NBx
25x-NB
25x-NB3OMe
  • 25B-NB3OMe
  • 25C-NB3OMe
  • 25D-NB3OMe
  • 25E-NB3OMe
  • 25H-NB3OMe
  • 25I-NB3OMe
  • 25N-NB3OMe
  • 25P-NB3OMe
  • 25T2-NB3OMe
  • 25T4-NB3OMe
  • 25T7-NB3OMe
  • 25TFM-NB3OMe
25x-NB4OMe
  • 25B-NB4OMe
  • 25C-NB4OMe
  • 25D-NB4OMe
  • 25E-NB4OMe
  • 25H-NB4OMe
  • 25I-NB4OMe
  • 25N-NB4OMe
  • 25P-NB4OMe
  • 25T2-NB4OMe
  • 25T4-NB4OMe
  • 25T7-NB4OMe
  • 25TFM-NB4OMe
25x-NBF
25x-NBMD
  • 25B-NBMD
  • 25C-NBMD
  • 25D-NBMD
  • 25E-NBMD
  • 25F-NBMD
  • 25H-NBMD
  • 25I-NBMD
  • 25P-NBMD
  • 25T2-NBMD
  • 25T7-NBMD
  • 25TFM-NBMD
25x-NBOH
25x-NBOMe
Atypical structures
25x-NMx
  • 25B-NMe7BF
  • 25B-NMe7BT
  • 25B-NMe7Bim
  • 25B-NMe7Box
  • 25B-NMe7DHBF
  • 25B-NMe7Ind
  • 25B-NMe7Indz
  • 25B-NMePyr
  • 25I-NMe7DHBF
  • 25I-NMeFur
  • 25I-NMeTHF
  • 25I-NMeTh
N-(2C)-fentanyl
  • N-(2C-B) fentanyl
  • N-(2C-C) fentanyl
  • N-(2C-D) fentanyl
  • N-(2C-E) fentanyl
  • N-(2C-G) fentanyl
  • N-(2C-H) fentanyl
  • N-(2C-I) fentanyl
  • N-(2C-IP) fentanyl
  • N-(2C-N) fentanyl
  • N-(2C-P) fentanyl
  • N-(2C-T) fentanyl
  • N-(2C-T-2) fentanyl
  • N-(2C-T-4) fentanyl
  • N-(2C-T-7) fentanyl
  • N-(2C-TFM) fentanyl
3C-x
4C-x
DOx
HOT-x
MDxx
Mescaline (subst.)
TMAs
  • TMA
  • TMA-2
  • TMA-3
  • TMA-4
  • TMA-5
  • TMA-6
Others
Piperazines
Tryptamines
alpha-alkyltryptamines
x-DALT
x-DET
x-DiPT
x-DMT
x-DPT
Ibogaine-related
x-MET
x-MiPT
Others
Others
Dissociatives
(NMDAR
antagonists)
Arylcyclo‐
hexylamines
Ketamine-related
PCP-related
Others
Adamantanes
Diarylethylamines
Morphinans
Others
Deliriants
(mAChR
antagonists)
Others
Cannabinoids
(CB1 agonists)
Natural
Synthetic
AM-x
CP x
HU-x
JWH-x
Misc. designer cannabinoids
D2 agonists
GABAA
enhancers
Inhalants
(Mixed MOA)
κOR agonists
Oneirogens
Others
  • v
  • t
  • e